Small Molecules
11 September 2017
AbbVie’s Upadacitinib (ABT-494) Meets All Primary and Ranked Secondary Endpoints in Second Phase 3 Study in Rheumatoid Arthritis11 September 2017
ESSA Pharma Announces Results from the Phase 1 Clinical Trial of EPI-506 for Treatment of mCRPC and Updates Clinical and Strategic Plans11 September 2017
Galderma: Combined Use of Rosacea Therapies Ivermectin 1% Cream and Brimonidine 0.33% Gel Evaluated in MOSAIC Study11 September 2017
Janssen to Discontinue Hepatitis C Development Program11 September 2017
First Patients Enrolled in UK’s Early Access to Medicines Scheme for Santhera’s Raxone® in Duchenne Muscular Dystrophy (DMD)10 September 2017
Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of BLU-554 in Patients with Advanced Hepatocellular Carcinoma9 September 2017
Phase 3 COLUMBUS Part 2 Results in BRAF-Mutant Melanoma Presented at European Society for Medical Oncology Congress9 September 2017
AstraZeneca’s Tagrisso shows potential as a new standard of care in 1st-line EGFR-mutated lung cancer at ESMO 2017 Congress8 September 2017
Biophytis Clinical Stage Drug-Candidate Sarconeos Demonstrates Efficacy in Preclinical Models of Duchenne Muscular Dystrophy8 September 2017
Kura Oncology Announces Positive Phase 2 Study for Tipifarnib in HRAS Mutant Head and Neck Cancer7 September 2017
Adamas Announces Topline Phase 1b Data of ADS-4101 (lacosamide) for the Treatment of Partial Onset Seizures in Epilepsy7 September 2017
AbbVie’s Upadacitinib (ABT-494) Meets Primary Endpoint in Phase 2b Study in Atopic Dermatitis7 September 2017
Verona Pharma Announces Positive Top-Line Data from Phase 2a Clinical Trial in COPD with RPL554 Dosed in Addition to Tiotropium (Spiriva®)7 September 2017
Duaklir significantly improves lung function in COPD patients6 September 2017
Medimetriks Announces Phase 2 Study Results Demonstrating Early Itch Relief for Topical PDE4 Inhibitor MM36 in Patients with Atopic Dermatitis6 September 2017
Actelion Receives FDA Approval Of TRACLEER® (bosentan) For Use In Pediatric Patients With Pulmonary Arterial Hypertension6 September 2017
Sanford Burnham Prebys and Daiichi Sankyo Announce Enrollment of First Subject in a Phase 1 Clinical Trial of DS-1211 in Healthy VolunteersNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports